Literature DB >> 16051945

Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?

Ramesh Rengan1, Philip Paty, W Douglas Wong, Jose Guillem, Martin Weiser, Larissa Temple, Leonard Saltz, Bruce D Minsky.   

Abstract

PURPOSE: Patients with cT2N0 distal rectal cancer do not require adjuvant therapy. However, when a patient refuses an abdominoperineal resection (APR), is there an alternative? The purpose of this trial is to determine whether preoperative external-beam radiation therapy can increase the rate of sphincter preservation for patients with distal cT2N0 adenocarcinoma of the rectum. PATIENTS AND METHODS: Between April 1988 and October 2003, 27 patients with distal rectal adenocarcinoma staged T2 by clinical and/or endorectal ultrasound who were judged by the operating surgeon to require an APR were treated with preoperative pelvic radiation alone (50.4 Gy). Surgery was performed 4 to 7 weeks later. If pathologic positive pelvic nodes were identified, postoperative adjuvant chemotherapy was recommended. The median follow-up was 55 months (range, 9 to 140 months).
RESULTS: The pathologic complete response rate was 15% and 78% of patients underwent a sphincter-sparing procedure. The crude incidence of local failure for patients undergoing a sphincter sparing procedure was 10% and the 5-year actuarial incidence was 13%. The actuarial 5-year survival for patients undergoing sphincter preservation was as follows: disease-free, 77%; colostomy-free, 100%; and overall, 85%. Using the Memorial Sloan-Kettering Cancer Center sphincter function score, 54% of those undergoing a sphincter-sparing procedure had good/excellent bowel function at 12 to 24 months after surgery, and 77% had good/excellent function at 24 to 36 months after surgery.
CONCLUSION: Our data suggest that for patients with cT2N0 distal rectal cancer who require an APR, preoperative pelvic radiation improves sphincter preservation without an apparent compromise in local control or survival.

Entities:  

Mesh:

Year:  2005        PMID: 16051945     DOI: 10.1200/JCO.2005.10.041

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

1.  Usefulness of two independent histopathological classifications of tumor regression in patients with rectal cancer submitted to hyperfractionated pre-operative radiotherapy.

Authors:  Lukasz Liszka; Ewa Zielińska-Pajak; Jacek Pajak; Dariusz Gołka; Jacek Starzewski; Zbigniew Lorenc
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

2.  Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection.

Authors:  Oliver K Jawitz; Mohamed A Adam; Megan C Turner; Brian F Gilmore; John Migaly
Journal:  Surgery       Date:  2019-03-21       Impact factor: 3.982

3.  Long-term oncologic results of patients with distal rectal cancer treated by local excision with or without adjuvant treatment.

Authors:  Byung Soh Min; Nam Kyu Kim; Yong Taek Ko; Kang Young Lee; Seung Hyuk Baek; Chang Hwan Cho; Seung Kook Sohn
Journal:  Int J Colorectal Dis       Date:  2007-06-12       Impact factor: 2.571

4.  Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database.

Authors:  Y Nancy You; Nancy N Baxter; Andrew Stewart; Heidi Nelson
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

5.  [Role of neoadjuvant radiotherapy for rectal cancer : Is MRI-based selection a future model?].

Authors:  Y Kulu; T Hackert; J Debus; M-A Weber; M W Büchler; A Ulrich
Journal:  Chirurg       Date:  2016-07       Impact factor: 0.955

Review 6.  Current approaches and challenges for monitoring treatment response in colon and rectal cancer.

Authors:  Elizabeth McKeown; Daniel W Nelson; Eric K Johnson; Justin A Maykel; Alexander Stojadinovic; Aviram Nissan; Itzhak Avital; Björn Ldm Brücher; Scott R Steele
Journal:  J Cancer       Date:  2014-01-01       Impact factor: 4.207

7.  Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

Authors:  Antonio Avallone; Maria Carmela Piccirillo; Paolo Delrio; Biagio Pecori; Elena Di Gennaro; Luigi Aloj; Fabiana Tatangelo; Valentina D'Angelo; Cinzia Granata; Ernesta Cavalcanti; Nicola Maurea; Piera Maiolino; Franco Bianco; Massimo Montano; Lucrezia Silvestro; Manuela Terranova Barberio; Maria Serena Roca; Massimo Di Maio; Pietro Marone; Gerardo Botti; Antonella Petrillo; Gennaro Daniele; Secondo Lastoria; Vincenzo R Iaffaioli; Giovanni Romano; Corradina Caracò; Paolo Muto; Ciro Gallo; Francesco Perrone; Alfredo Budillon
Journal:  BMC Cancer       Date:  2014-11-24       Impact factor: 4.430

8.  Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy.

Authors:  Nir Wasserberg; Yulia Kundel; Ofer Purim; Andrei Keidar; Hanoch Kashtan; Eran Sadot; Eyal Fenig; Baruch Brenner
Journal:  Radiat Oncol       Date:  2014-10-22       Impact factor: 3.481

9.  Outcome of Local Excision Following Preoperative Chemoradiotherapy for Clinically T2 Distal Rectal Cancer: A Multicenter Retrospective Study (KROG 12-06).

Authors:  Jae Myoung Noh; Won Park; Jae-Sung Kim; Woong Sub Koom; Jin Hee Kim; Doo Ho Choi; Hee Chul Park
Journal:  Cancer Res Treat       Date:  2014-07-15       Impact factor: 4.679

10.  Influence of Preoperative Chemoradiotherapy on the Surgical Strategy According to the Clinical T Stage of Patients With Rectal Cancer.

Authors:  In Ja Park; Jong Lyul Lee; Yong Sik Yoon; Chan Wook Kim; Seok-Byung Lim; Jong Seok Lee; Seong Ho Park; Jin Hong Park; Jong Hoon Kim; Chang Sik Yu; Jin Cheon Kim
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.